The Canadian Agency for Drugs and Technologies in Health (CADTH) has launched the CADTH Pharmaceutical Reviews Update. This is a new consolidated publication that will communicate updates to CADTH’s drug review process. It replaces previous individual publications, including CDR Update, pCODR Update, Therapeutic Review Update, and Updates for Patient Groups. In this first issue of the CADTH Pharmaceutical Reviews Update, among other announcements, CADTH invites stakeholder comments on a number of proposals, and announces changes to the Pan-Canadian Oncology Drug Review.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
